Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$75.3MCash on Hand
CF+ Cash Runway
Follow KMDA by emailGet an email when KMDA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about KMDA, unsubscribe in one click. Privacy
📣 What KMDA Says Is Next
IN 2027 · “KAMADA REPORTS RECORD-HIGH FIRST NINE MONTHS 2026 FINANCIAL RESULTS; INCREASES 2026 ANNUAL GUIDANCE AND PROJECTS DOUBLE-DIGIT GROWTH IN REVENUES AND PROFITABILITY IN 2027 Exhibit 99.2 Kamada Reports Record-High First Nine Months 2026 Financial Results; Increases 2026 Annual Guidance and Projects Double-Digit Growth in Revenues and Profitability in 2027”
Company press release, Nov 9, 2026 · SEC filing
In 2026 · “We are reiterating our 2026 annual guidance of $200 million to $205 million in revenues and $50 million to $53 million of adjusted EBITDA, respectively, representing 12% and 23% growth when comparing 2026 guidance mid-points to 2025 results.” “In 2026, our focus remains on the expansion of our entire commercial product portfolio, including our six FDA-approved specialty plasma-derived products.”
Company press release, May 13, 2026 · SEC filing
IN 2026 · “KAMADA ANNOUNCES DISCONTINUATION OF ITS PHASE 3 INHALED AAT CLINICAL TRIAL; REITERATES 2025 FULL-YEAR GUIDANCE AND PROJECTS DOUBLE-DIGIT GROWTH IN REVENUES AND PROFITABILITY IN 2026 Exhibit 99.1 Kamada Announces Discontinuation of its Phase 3 Inhaled AAT Clinical Trial; Reiterates 2025 Full-Year Guidance and Projects Double-Digit Growth in Revenues and Profitability in 2026”
Company press release, Dec 8, 2025 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 9, 2026 ·
Shareholder vote Kamada's board declared a cash dividend of $0.14 per share, about $8.0 million in total, payable December 9, 2026 to holders of record on November 19, 2026. This follows $24.2 million in dividends paid earlier this year. Form 6-K · SEC filing · Press release
Nov 2, 2026 ·
Earnings Kamada will release third quarter and nine months ended September 30, 2026, financial results before market open on Monday, November 9, 2026, with a conference call at 8:30am ET that day. Form 6-K · SEC filing · Press release
Oct 6, 2026 ·
Deal Kamada launched two more biosimilars in Israel, Ustekinumab-Kamada (a Stelara biosimilar) and Enoxaparin-Kamada (a Clexane biosimilar). It expects about $4 million in 2026 biosimilar sales, about $10 million in 2028, and $20 million to $25 million in annual revenue by 2030. Form 6-K · SEC filing · Press release
Oct 5, 2026 ·
Regulatory Kamada responded to an SEC comment letter on its 2025 Form 20-F, which questioned capitalizing inventory produced before regulatory approval. The company said it did not capitalize such costs in 2025 or 2024 and will expand its accounting policy disclosure in future filings. Form 6-K · SEC filing · Press release
Sep 17, 2026 ·
Kamada says it has sufficient KedRAB inventory and manufacturing capacity to meet increased U.S. demand, following a CDC Health Advisory reporting a significant year-over-year rise in rabies exposures. KedRAB is one of two FDA-approved anti-rabies immunoglobulin products, with the U.S. Form 6-K · SEC filing · Press release
Sep 10, 2026 ·
Kamada CEO Amir London will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026, at 2:30 p.m. Eastern Time, and will hold one-on-one investor meetings. Form 6-K · SEC filing · Press release
Sep 9, 2026 ·
Financing Kamada filed a shelf registration to sell up to $50,000,000 of ordinary shares from time to time, with pricing and terms to be set in future prospectus supplements. The Nasdaq price was $8.54 on September 4, 2026. Form F-3 · SEC filing
Sep 3, 2026 ·
Kamada will withhold 25% of its $0.17 per share cash dividend, about $9.8 million total, payable September 17, 2026, to Nasdaq shareholders of record August 27, 2026. Eligible holders in treaty countries can apply for a reduced withholding rate by October 7, 2026. Form 6-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Nov 2020 · Phase 1/2 · Results Expected · Safety, PK and PD of Kamada Anti-SARS-CoV-2 in COVID-19 Registry primary completion date, not a results date
Nov 2019 · Phase 3 · Results Expected · Post-marketing Study of KamRAB Administered as a Single Dose With Active Rabies Vaccine in Children Exposed to Rabies Registry primary completion date, not a results date
Apr 2019 · Phase 2 · Results Expected · Study to Evaluate the Safety and Efficacy of Intravenous Glassia® Treatment in Lung Transplantation Registry primary completion date, not a results date
Feb 2017 · Phase 2 · Results Expected · Phase II Study to Evaluate the Efficacy and Safety of Glassia® in Type-1 Diabetes Registry primary completion date, not a results date
Feb 2016 · Phase 2 · Results Expected · Phase II, Safety and Efficacy Study of Kamada-alpha-1-antitrypsin (AAT) for Inhalation" Registry primary completion date, not a results date
Nov 2014 · Phase 2/3 · Results Expected · International Study Evaluating the Safety and Efficacy of Inhaled, Human, Alpha-1 Antitrypsin (AAT) in Alpha-1 Antitrypsin Deficient Patients With Emphysema Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
KMDA holds $75.3M in cash and short-term investments and its operations are currently cash-flow neutral or positive.
Share count 57,686,056 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full KMDA picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for KMDA and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.